Search Medical Condition
Please enter condition
Please choose location from dropdown

Fu Zhou, China Clinical Trials

A listing of Fu Zhou, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (166) clinical trials

A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B

Patents who were treated with NA at least one year and achieved hepatitis B virus (HBV) DNA suppression and HBsAg level<3000 international unit (IU) /mL are enrolled in this study, they are assigned into two groups, in group I, patients will receive pegylated interferon plus entecavir/tenofovir for 48/72/96 weeks, in ...

Phase

0.0 miles

Learn More »

A Research in Pharmacogenomics and Accurate Medication of New Antiplatelet Drug Ticagrelor

It is general that there are many factors for individual differences of drugs in clinical application, of which genetic factors accounted for more than 20%. Ticagrelor is a new-type receptor antagonist of P2Y12 and it is not affected by the influence of CYP2C19 polymorphism. With lack of predicted biomarkers, especially ...

Phase N/A

0.0 miles

Learn More »

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast ...

Phase

0.0 miles

Learn More »

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

EGFR-TKIs are the standard first-line treatment option for EGFR-mutant NSCLC. After a randomized phase II trial, JO25567 was presented at 2014 ASCO, the synergistic effect of progression-free survival(PFS) could be expected when EGFR TKI, Gefitinib is combined with Antiangiogenesis agent thalidomide, . Even Chinese and Japanese are classified as Asian ...

Phase

0.0 miles

Learn More »

Apatinib Combined With SOX Neoadjuvant Chemotherapy for Locally Advanced Gastric Cance

We star a multicentre, one-armed, clinical pilot trial intends to investigate the safety and effectiveness of Apatinib Combined With Oxaliplatin, Gimeracil and Oteracil Porassium Capsules Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer(cT2-4/N+M0)

Phase

0.0 miles

Learn More »

Effect of Photodynamic Therapy on Deep Caries in Permanent Tooth A Controlled Clinical Trial

The aim of the proposed study is to assess the clinical effect of photodynamic therapy (PDT)using LED on dentin with carious lesions in permanent teeth. Patients with molars exhibiting deep carious lesions on the occlusal surface indicated for restorative treatment will be randomly allocated to two groups: Group 1 -Control ...

Phase

0.0 miles

Learn More »

A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast

In this study, the investigators conducted a hospital-based retrospective clinical study, recruiting female advanced breast cancer patients from 14 tertiary hospitals at 7 classic geographic regions, to study the clinical epidemiologic characteristics of advanced breast cancer and the current standard of clinical diagnosis and treatment in order to provide references ...

Phase N/A

0.0 miles

Learn More »

Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus

For giant or large invasive prolactinomas involving the cavernous sinus, whether the drug can be safely withdrawn after the tumor volume and prolactin(PRL) level have been effectively controlled through pharmacological treatment still remains unknown. The study objects are patients with invasive prolactinomas involving the cavernous sinus, which were invaded the ...

Phase N/A

0.0 miles

Learn More »

Adjuvant IFN- for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression

BACKGROUND: Postoperative interferon-alpha (IFN-alpha) therapy improved survival in patients with hepatocellular carcinoma (HCC). MiR-26 is a predictive marker for the effect of postoperative interferon-alpha treatment in patients with HCC. Our study is to identify the effect of postoperative IFN-alpha treatment in patients with a low miR-26 expression in tumor after ...

Phase

0.0 miles

Learn More »

Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma

This clinical study is designed as a phase 3,multicenter, double-blind, randomized, controlled study,to evaluate the efficacy and safety of nimotuzumab combined with TP compared with TP as first-line treatment for the metastatic esophageal squamous carcinoma.The main endpoint is OS.

Phase

0.0 miles

Learn More »